©2022 Stanford Medicine
Effects of Epidural Lidocaine on the Pharmacokinetic and Pharmacodynamic Profiles of DepoDur® After Cesarean Delivery
Trial ID: NCT00804609
To evaluate the levels of morphine in a patient's blood when morphine is given into the epidural space in the form of DepoDur® either alone or following a dose of lidocaine also given in the epidural space.
A Study to Evaluate the Effects of Epidural Lidocaine Administration on the Pharmacokinetic and Pharmacodynamic Profiles of DepoDur® (Morphine Sulfate Extended-release Injection) in Patients Undergoing Cesarean Delivery
Inclusion criteria will include healthy parturients between the ages of 18 and 40 who have
American Society of Anesthesiologists physical status I or II, have an uncomplicated,
singleton, term pregnancy, and are scheduled to undergo cesarean delivery.
Exclusion criteria for the study will included refusal to participate, American Society of
Anesthesiologists physical status III or higher or any severe uncontrolled medical
condition, significant systemic medical or obstetric disease, morbid obesity, opioid,
Nonsteroidal Antiinflammatory Drug (NSAID), or local anesthetic allergy or intolerance,
chronic analgesic or antidepressant use, accidental dural puncture, ineffective spinal or
epidural, and conversion to general anesthesia.
drug: DepoDur following epidural lidocaine
drug: DepoDur following spinal anesthetic
School of Medicine
300 Pasteur Drive
Stanford, CA 94305